Why do studies disagree about platelet-rich plasma (PRP)?

What did the knee studies find?

Studies don't agree about knee soreness after PRP. Some found relief during later months. Other careful studies found little added relief. The findings don't give one clear answer.

One study assigned treatments by chance. PRP was tested against saline, which is sterile salt water. Both groups felt better over time. PRP didn't reduce soreness more than the salt water.

Most studies involved knees with arthritis. They don't answer every shoulder or hip question. They also can't settle every tendon problem. Ask whether the people studied were like you.

Can a personal success story prove it works?

Someone may say PRP helped greatly. That's anecdotal, or one person's report. The relief may feel quite real. It still can't predict what you'll feel.

Joint soreness often rises and falls. Rest or lighter activity may help too. The relief isn't always from PRP. You also can't know how long it lasted.

Ask whether that person ever needed surgery. If surgery wasn't likely, PRP can't claim credit for avoiding it. Ask whether soreness later returned. A success report can guide questions, not your choice.

Which study details can help me decide?

First, find which joint the study covered. Check how much wear the people had. Ask whether PRP kept more white blood cells. Also ask how much platelet-rich liquid they received.

Check when the study measured soreness. Early relief doesn't always last. Find what treatment PRP was compared with. A result without another treatment is less useful.

Keep using safe home care while you decide. Track sleep, walking, and swelling. Take your notes to the visit. QC Kinetix medical providers, or trained clinicians, can review the exam and describe blood-based regenerative treatments.

Sources

1. RESTORE, the largest and most rigorously blinded placebo-controlled PRP trial in knee OA (n=288, participant-, injector- and assessor-blinded), gave three weekly injections of a commercial leukocyte-poor PRP or saline. At 12 months the change in knee pain was -2.1 vs -1.8 points (difference -0.4; 95% CI -0.9 to 0.2; P=.17) and the change in medial tibial cartilage volume was -1.4% vs -1.2% (difference -0.2%; P=.81). Twenty-nine of 31 prespecified secondary outcomes showed no between-group difference. The authors concluded the findings do not support the use of PRP for knee OA.

   Bennell KL, et al. — Effect of Intra-articular Platelet-Rich Plasma vs Placebo Injection on Pain and Medial Tibial Cartilage Volume in Patients With Knee Osteoarthritis: The RESTORE Randomized Clinical Trial.. JAMA, 2021. DOI: 10.1001/jama.2021.19415.

2. A Bayesian network meta-analysis of 48 Level I-II randomized trials (9,338 knees) with a minimum 6-month follow-up ranked the four commonest intra-articular injections. HA and PRP both significantly improved pain versus placebo; HA, PRP and BMAC all significantly improved function versus placebo. SUCRA rankings were PRP 91.54, BMAC 76.46, HA 53.12, corticosteroid 15.18 and placebo 13.70 - corticosteroid ranked barely above placebo at six months and beyond.

   Jawanda H, et al. — Platelet-Rich Plasma, Bone Marrow Aspirate Concentrate, and Hyaluronic Acid Injections Outperform Corticosteroids in Pain and Function Scores at a Minimum of 6 Months as Intra-Articular Injections for Knee Osteoarthritis: A Systematic Review and Network Meta-analysis.. Arthroscopy, 2024. DOI: 10.1016/j.arthro.2024.01.037.

3. A network meta-analysis restricted to LARGE randomized trials (at least 100 patients per group; 57 RCTs, 22,795 participants, 18 intra-articular interventions) found treatment effects were consistently larger in the 35 high-risk-of-bias trials than in the 22 low/unclear-risk trials. In the main analysis excluding high-risk trials, triamcinolone had the highest probability of exceeding the minimal important difference at weeks 2 and 6; hyaluronic acid had no effect on pain (SMD -0.04, 95% CrI -0.19 to 0.11, 11 trials) but higher odds of dropouts due to adverse events (OR 2.01) and of serious adverse events (OR 1.86). The effects of 16 of the 18 interventions were smaller than the MID and most were consistent with placebo effects.

   Pereira TV, et al. — Effectiveness and safety of intra-articular interventions for knee and hip osteoarthritis based on large randomized trials: A systematic review and network meta-analysis.. Osteoarthritis and Cartilage, 2025. DOI: 10.1016/j.joca.2024.08.014.

4. A meta-analysis of 18 Level I trials (811 PRP vs 797 HA patients, mean follow-up 11.1 months) found mean WOMAC total improvement of 44.7% with PRP versus 12.6% with HA (P<.01). Six of 11 VAS-based studies and 3 of 6 IKDC-based studies favoured PRP significantly. In the subanalysis, leukocyte-POOR PRP was associated with significantly better subjective IKDC scores than leukocyte-rich PRP.

   Belk JW, et al. — Platelet-Rich Plasma Versus Hyaluronic Acid for Knee Osteoarthritis: A Systematic Review and Meta-analysis of Randomized Controlled Trials.. American Journal of Sports Medicine, 2021. DOI: 10.1177/0363546520909397.

5. A network meta-analysis of 64 trials (9,710 patients) that deliberately separated WITHIN-CLASS variants found high-molecular-weight hyaluronic acid was the only treatment whose confidence interval lay entirely above the minimal important difference for BOTH pain and function. PRP's pain estimate also cleared the MID but varied across sensitivity analyses, leaving its efficacy uncertain; extended-release corticosteroid showed possible benefit over standard-release corticosteroid.

   Phillips M, et al. — Differentiating factors of intra-articular injectables have a meaningful impact on knee osteoarthritis outcomes: a network meta-analysis.. Knee Surgery, Sports Traumatology, Arthroscopy, 2020. DOI: 10.1007/s00167-019-05763-1.

6. The ESSKA-ORBIT European consensus on blood-derived orthobiologics graded 28 question-statement sets; only 9 of 28 had high-level scientific support. Three statements reached grade A: that there is enough preclinical and clinical evidence to support PRP use in knee OA; that clinical evidence shows effectiveness in MILD TO MODERATE knee OA (KL grade 3 or lower); and that PRP provides a longer effect than the short-term effect of corticosteroid with a safer profile. The panel regarded PRP as a valid and possible first-line injectable option for KL grades 1-3.

   Laver L, et al. — The use of injectable orthobiologics for knee osteoarthritis: A European ESSKA-ORBIT consensus. Part 1-Blood-derived products (platelet-rich plasma).. Knee Surgery, Sports Traumatology, Arthroscopy, 2024. DOI: 10.1002/ksa.12077.

7. The 2025 Cochrane review of stem cell injections for knee osteoarthritis pooled 25 randomised trials (1,341 participants) and found that, compared with placebo injection, stem cell injection MAY slightly improve pain (1.2 points better on a 0-10 scale, 7 studies, 445 participants) and function (14.2 points better on a 0-100 scale, 7 studies, 432 participants) up to six months - both rated LOW-certainty evidence, downgraded for indirectness (cell source, preparation and dose varied across studies) and suspected publication bias, since up to three larger RCTs were conducted and withdrawn before reporting results. Radiographic progression was not assessed in any included study.

   Whittle SL, et al. — Stem cell injections for osteoarthritis of the knee.. Cochrane Database of Systematic Reviews, 2025. DOI: 10.1002/14651858.CD013342.pub2.